Shares of Vertex Pharmaceuticals have moved 2.4% today, and are now trading at a price of $385.11. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 763,677 compared to the stock's average volume of 956,114.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). Based in Boston, United States the company has 4,800 full time employees and a market cap of $99,394,961,408.
The company is now trading -0.92% away from its average analyst target price of $388.67 per share. The 24 analysts following the stock have set target prices ranging from $315.0 to $456.0, and on average give Vertex Pharmaceuticals a rating of buy.
Over the last 52 weeks, VRTX stock has risen 27.0%, which amounts to a 12.0% difference compared to the S&P 500. The stock's 52 week high is $386.61 whereas its 52 week low is $282.21 per share. With its net margins declining an average -10.5% over the last 6 years, Vertex Pharmaceuticals may not have a strong enough profitability trend to support its stock price.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 9,505,000 | 3,364,900 | 35 | -5.41 |
| 2022 | 8,930,700 | 3,322,000 | 37 | 19.35 |
| 2021 | 7,574,400 | 2,342,100 | 31 | -29.55 |
| 2020 | 6,205,700 | 2,711,700 | 44 | 57.14 |
| 2019 | 4,162,800 | 1,176,810 | 28 | -59.42 |
| 2018 | 3,047,597 | 2,096,896 | 69 |
